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Abstract
Purpose: There is a lack of information in ethnic minority groups with regard to presentation and treatment of early node-
positive breast cancer. We carried out a retrospective study of patients referred to two tertiary cancer centers in South
Western Sydney, both of which serve a high proportion of this ethnic minority population.
Patients and methods: Women who had pathologically node-positive non-metastatic breast cancer (T1-3, N1-3, M0)
diagnosed between 2003 and 2006 were studied, with variables of interest being tumor size, number of positive nodes,
histological grade, hormone receptor status, age at diagnosis, country of birth and treatment. We compared the Asian and
Western subgroups with regard to tumor characteristics, treatment and clinical outcomes.
Results: A total of 652 eligible patients were identified, with a median follow-up of 6.1 years. Women with Asian
backgrounds (n = 125, 20%) were significantly younger at presentation (48 years versus 55 years, p-value,0.0001) and more
likely to undergo mastectomy (53% versus 39%, p-value 0.0009) and chemotherapy (86% versus 72%, p-value 0.0063) than
their non-Asian counterparts. Tumor stage, grade and receptor status were not statistically different between these two
groups. There were also no differences in disease-free survival and overall survival, with medians of 12.7 and 14.8 years
respectively.
Conclusion: Women of Asian background are younger at diagnosis, which may reflect population epidemiology and likely
results in higher uptake of chemotherapy. Higher mastectomy rates may be influenced by cultural factors. Future research is
warranted to investigate potential differences in tumor biology, psychosocial, economic and cultural factors.
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Introduction
The recognized prognostic features in non-metastatic, node-
positive breast cancer that influence treatment decisions and
outcome include patient age, tumor size, number and percentage
of positive nodes, tumor grade, hormone receptor status and Her-2
status. Studies of outcome according to race in the English
literature are relatively sparse but suggest that South Asian women
living in Europe are significantly younger than non-Asian women
at diagnosis, present with larger tumors, and have higher
mastectomy rates [1]. Younger peak incidence of diagnosis is also
evident in other studies [2]. Studies on survival also suggest a
superior outcome in the South Asian population [3,4]. It remains
unclear as to whether these differences in presentation and
outcome are attributable to biology or acculturation [4,5].
Australia has one of the largest immigrant populations in the
world, with 4.4 million overseas-born people and 1 in 4 people
residing in Australia being born overseas [6] out of a total
population of around 23 million [7]. Given the diverse cultural
makeup and the increasing number of Asian immigrants in
Australia, there is a need for studies investigating racial disparities.
The Australian Institute of Health and Welfare, in partnership
with the Australian Cancer Database and the Australasian
Association of Cancer Registries, records information on breast
cancer statistics in Australia [6]. Breast cancer incidence has more
than doubled between 1982 and 2008. Age-standardized incidence
rates increased in the period 1982 to 1995 from 81–116 to 110–
118 (per 100000). There were 37 females diagnosed with this
disease every day in 2008 and this is projected to increase to 47 per
day in 2020, given the aging population. The five-year relative
survival has improved between the periods 1982–1987 and 2006–
2010, from 72% to 89% respectively, likely due to improved
screening programs and treatments. Subgroups of patients were
noted to have poorer survival namely females in remote areas,
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those of lower socioeconomic status, and Aboriginal and Torres
Strait Islander patients, with 5-year survival rates of 84%, 88%
and 69%, respectively. Lower incidences of, and lower mortality
from, breast cancer were noted in the immigrant population which
includes the Asian (inclusive of South-east Asian, South and
central Asian, North-east Asian) and Middle-eastern population.
This may be due to the ‘healthy migrant effect’ where the
immigrant population has been self-selected for better health [8].
However, there is a lack of information with regard to presentation
and treatment of early node-positive breast cancer in specific
ethnic minority migrant groups. Hence, we sought to determine
the patterns of care in the ethnic minority Asian population
referred to two tertiary centres: the Liverpool local government
area (LGA), and Campbelltown LGA, which serve the Sydney
South West Local Health District, an area of over 6380 square
kilometers, comprising 20% of the population in the New South
Wales State [9]. Liverpool is approximately 35 kilometers south-
west of central Sydney and Campbelltown is a further 20
kilometers south-west of Liverpool. Approximately 40% of the
catchment population have a non-English speaking background,
comprising one of the most ethnically diverse health service areas
in Australia. The Liverpool LGA serves 164,603 people, with
53.8% being Australian born, 43.8% in the 25–54 years age
group, 1.3% Indigenous population, and 47.1% stating that
English is the only language spoken at home. Campbelltown LGA
serves an area encompassing 143, 076 people, with 66.8% being
Australian born, 42.1% in the 25–54 years age group, and 72.2%
stating that English is the only language spoken at home.
Patients and Methods
Ethics Statement
Ethics approval was obtained on 2nd November 2011 from the
South Western Sydney Local Health District Human Research
Ethics Committee, reference number LNR/11/LPOOL/404.
The institutional review board waived the need for written
informed consent from the participants as the project was deemed
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aThe percentages may not add up to one hundred percent due to rounding.
doi:10.1371/journal.pone.0095852.t001
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to be in the low or negligible risk category. Information was de-
identified prior to analysis.
A retrospective study of patients with node-positive, non-
metastatic breast cancer diagnosed between 2003 and 2006 was
performed. All data were extracted from an electronic database
(Mosaiq Version 2.4, Elekta AB, Stockholm, Sweden) and follow-
up data were manually obtained. Variables of interest included
tumor size, positive nodes, grade, hormone receptor status, age
and race. Outcomes of interest included progression-free survival
and overall survival.
The primary aim was to compare the Western population with
the Asian population for variables and outcomes of interest, using
Fisher’s exact test. The Indian sub-continental population (South
Asian), East Asian, South-east Asian, Middle-eastern and Polyne-
sian patients were classed as Asian in our analysis. The Australian,
New Zealander, North American and European population were
classed as Western. The secondary aim was to examine these
variables for disease-free survival by performing univariate and
multivariate analyses using a Cox regression model. The
proportional hazards assumption was not met for receptor status
and grade, so the analysis was stratified by receptor status. Data
analysis was generated using SAS Enterprise Guide software
(Version 5.1 for Windows, copyright  2012 SAS Institute Inc).
Results
The total number of patients eligible for the study was 652, and
baseline characteristics are displayed in table 1. The median
follow-up duration was 6.1 years (range from 1 month to 25 years).
Median age was 52.5 years, median tumor size 22 mm, with a
median of 2 positive nodes and median of 18 total nodes dissected.
Grade 1, 2 and 3 tumors represented 20%, 41% and 37% of the
study group, respectively. Seventy-eight percent of patients had
tumors that were estrogen and/or progesterone receptor positive.
Infiltrating ductal carcinoma NOS comprised 84%, with lobular
carcinoma compromising 9%; medullary, mucinous, papillary,
tubular and neuroendocrine carcinomas each comprised less than
1%, whereas male breast cancers comprised 0.6%. Mastectomy
Table 2. Correlation of Asian and Western populations with variables of interest, using Fisher’s exact test.
Western Asian Fisher’s exact test p-value
Variable N % N %
Age ,0.0001
,50 years 154 34.5 79 63.2
$50 years 293 65.6 46 36.8
Gradea 0.9638
1 88 20.1 25 20.3
2 184 42.0 53 43.1
3 166 37.9 45 36.6
Tumor size 0.1541
#2 cm 205 45.9 48 38.4
.2 cm 242 54.1 77 61.6
Positive nodes 0.4859
1–3 313 70.0 82 65.6
4–9 79 17.7 28 22.4
10+ 55 12.3 15 12.0
Hormone receptor statusb 0.3593
Negative 77 17.7 26 21.3
Positive 357 82.3 96 78.7
Radiotherapyc 0.2828
No 72 16.8 26 21.3
Yes 357 83.2 96 78.7
Chemotherapyd 0.0009
No 122 28.5 17 14.1
Yes 306 71.5 104 86.0
Surgerye 0.0063
Mastectomy 164 38.8 63 52.9
Wide local excision 259 61.2 56 47.1
Endocrine therapyf 0.5141
No 82 19.1 26 22.0
Yes 347 80.9 92 78.0
a–fAnalyses excluding missing data in agrade: Western n = 9, Asian n= 2, breceptor: Western n= 13, Asian n = 3, cradiotherapy: Western n= 18, Asian n = 3,
dchemotherapy: Western n = 19, Asian n= 4, esurgery: Western n = 24, Asian n= 6, fendocrine therapy: Western n = 18, Asian n= 7.
doi:10.1371/journal.pone.0095852.t002
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occurred in 38% and wide local excision in 55%. Adjuvant
radiotherapy and chemotherapy was delivered to 79% and 70% of
patients respectively. Hormone therapy was prescribed for 98% of
patients who were hormone receptor positive.
Sixty-nine percent of the patient population (n= 447) were
classed as Western, whereas the South Asian, East Asian and
South-east Asian subpopulations comprised 12%, Middle-eastern
6% and Polynesian 2% of the patient population (n = 125). The
correlation of race with variables of interest is shown in table 2.
Age at diagnosis was significantly lower in Asian patients, with
63% diagnosed under the age of 50 (p-value ,0.0001). Median
age in the Asian population was 48 years compared to 55 years in
the Western population. Tumor grade, size, degree of nodal
positivity and receptor status were similar in the two groups. A
significantly higher proportion of Asian patients received chemo-
therapy (86% compared to 72%, p-value 0.0009) and underwent
mastectomy (53% compared to 39%, p-value 0.0063). Uptake of
hormonal therapy and radiotherapy did not significantly differ
between the two groups.
The median disease-free survival was 12.7 years and overall
survival was 14.8 years. Univariate analysis identified tumor size,
positive nodes, tumor grade, hormone receptor status and type of
surgery to be significant variables for disease-free survival (table 3).
Multivariate analysis was performed, stratified by receptor status,
with positive hormone receptor status correlating with better
survival than patients with negative receptor status. In the receptor
positive group, tumor size, positive lymph nodes and grade
remained significant variables for disease-free survival (table 4).
Disease-free survival in the Asian and Western groups was not
significantly different in univariate and multivariate analyses.
Discussion
The Asian population in our study were significantly younger at
diagnosis, were more likely to receive chemotherapy and more
likely to undergo mastectomy than the Western population. The
age disparity is consistent with the literature suggesting similar
characteristics in ethnic minority groups in North America and the
United Kingdom. We did not find a difference in tumor size or
surgical stage between the Western and Asian population.
However, others have identified differences - South Asian women
living in Europe were significantly younger at diagnosis, had larger
tumors at presentation, and had higher mastectomy rates than the
British-native population in one published study [1]. Another
Table 3. Univariate analysis for disease-free survival.
Variable Hazard Ratio Lower 95% CI Upper 95% CI p-value
Ethnic group
Western Reference
Asian 0.93 0.63 1.38 0.7312
Grade 0.0037
1 Reference
2 2.56 1.44 4.53 0.0013
3 2.56 1.44 4.58 0.0015
Hormone receptor status
Negative Reference
Positive 0.47 0.33 0.68 ,0.0001
Radiotherapy
No Reference
Yes 0.92 0.62 1.37 0.6708
Chemotherapy
No Reference
Yes 0.90 0.62 1.30 0.5588
Surgery
Mastectomy Reference
Wide local excision 0.69 0.50 0.97 0.0309
Age
,50 Reference
$50 0.85 0.62 1.17 0.3236
Tumor Size
#2 cm Reference
.2 cm 1.73 1.25 2.41 0.0011
Positive nodes ,0.0001
1–3 Reference
4–9 1.16 0.77 1.75 0.473
10+ 2.79 1.89 4.13 ,0.0001
doi:10.1371/journal.pone.0095852.t003
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study also showed a significantly higher mastectomy rate in Asian
women, however this finding was not significant when adjusted for
node and size [1]. These differences in findings may mean our
study was under-powered to find a difference or it might mean that
Asian-origin patients choose mastectomy for reasons other than
tumor size. These include cultural and socio-ecological factors in
patient decision-making [10,11]. It may also be due to smaller
breast size, as some studies have found a higher incidence of small
breast size in the Asian population [12,13] as well as lower
absolute mammographic density [14].
The existing literature consistently reports a difference in peak
incidence of breast cancer between Asian and Western populations
[1,2,15], being 45 to 50 and 55 to 60 years, respectively. Younger
age at presentation, as noted in our study, may reflect the average
age of the ethnic minority population. The Sydney South West
Local Health District census data show that the population aged
between 15 and 44 comprised 47% of the population in this
region, as compared to 44% in the whole of the state of New South
Wales. This is in comparison to the population between 45 to 64,
and the population aged 65 and above, which were both lower in
this region (21% and 10% respectively) compared to whole state
(23% and 12% respectively) [9].
We found a higher uptake of chemotherapy in the Asian
population, which is likely related to younger age at diagnosis. We
thus carried out a further analysis, to adjust for age. After adjusting
for age, there were no differences in chemotherapy uptake
between the Asian and Western groups. A Chinese study also
reported that uptake of chemotherapy was significantly correlated
with age at diagnosis [16]. Other studies have demonstrated
disparities in uptake of chemotherapy in the American white and
non-white population [17–19]. These studies have found con-
trasting results in these two groups, likely due to the variation in
consideration of factors such as affluence, communication with the
physician, socio-cultural factors, and religiosity.
Acculturation may change the pattern of presentation, as shown
in a study of Asian-born American women who were found to
have a larger proportion of tumors larger than 1 cm (79%) than
the white population (70%). This difference was no longer evident
in American-born Asian women, reflecting higher utilization of
breast screening in the second-generation Asian immigrants [5].
Larger tumor size at presentation may also be due to a longer
duration of tumor development prior to presentation or delayed
presentation due to other factors.
Other studies suggest a difference not only in socioeconomic
and lifestyle factors, but possibly differences in biology [4]. Blacks,
Hispanic whites and American Indians were more likely to present
with larger tumors, with higher grade, more positive lymph nodes
and hormone negativity in comparison to non-Hispanic whites,
Asians and Pacific Islanders. Our study did not identify greater
stage at presentation for these patients. A South-east Asian study
based in two tertiary academic hospitals in Singapore and
Malaysia found Malay ethnicity to be associated with hormone-
negativity, poor differentiation and node metastases when adjusted
for tumor size, compared to Chinese and Indian ethnicities [15].
The 10-year survival outcomes adjusted for stage in South Asian
or the Indian sub-continental population in South-east England
were higher than in non-South Asian cases [3] at 73% and 65%
respectively. Another study found the Japanese population to have
better survival rates, while Hawaiian, Pacific Islanders, Vietnam-
ese and other Asians had poorer survival [4]. In contrast, we did
not find any differences in survival rates between the Asian and
non-Asian populations in South Western Sydney.
Our disease-free survival and overall survival findings are
consistent with the published literature in node-positive breast
cancer [20,21] [22,23], with a median disease-free survival of 12.7
years and overall survival of 14.8 years. The BIG1-98 study found
83% of women with hormone positive breast cancer were disease-
free at 5 years in the tamoxifen group [20], whereas the 5-year
disease-free survival was 74% in the node-positive subgroup. With
regard to prognostic variables, our univariate and multivariate
analyses found hormone receptor positivity, tumor size, positive
lymph nodes and grade to be correlated with disease-free survival.
These findings, as well as the medians obtained for the variables of
interest, are consistent with the literature [24–26]. The absence of
significant variables after stratification in the receptor negative
group may be due to lack of power, as 22% of patients in the
cohort were hormone receptor negative. Establishing the defini-
tion and age cutoff for young patients is controversial. Breast
cancer is uncommon in women less than 40 years of age. Most
series recognize 35 as the cutoff for age, but other series use a
Table 4. Multivariate analysis for disease-free survival in the hormone receptor positive cohort.
Variable Hazard Ratio Lower 95% CI Upper 95% CI p-value
Ethnic group
Western Reference
Asian 1.05 0.63 1.73 0.8621
Grade 0.0169
1 Reference
2 2.50 1.30 4.81 0.0059
3 2.51 1.27 4.96 0.0084
Tumor size
#2 cm Reference
.2 cm 1.72 1.11 2.66 0.0158
Positive nodes ,0.0001
1–3 Reference
4–9 0.98 0.57 1.71 0.9526
10+ 2.91 1.81 4.68 ,0.0001
doi:10.1371/journal.pone.0095852.t004
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cutoff of 50, presumably due to numbers. Using this cutoff, age
was not a significant prognostic factor in our study.
We recognize the limitations inherent in our retrospective study.
First, our data are based on electronic data base queries, which is
subject to human error and missing data, although we note that
less than 8% of patients had missing data across all variables.
Another variable of importance is the Her-2 status, which was
unavailable in our study cohort as routine confirmation of Her-2
status with in-situ hybridization in our health district pathology
department only began in early 2006. Our study would also
benefit from ongoing follow-up in order to improve data maturity.
However, the strengths of the study include individual patient
information on tumor characteristics and treatment modalities, as
well as comprehensive follow-up for disease-free survival.
Studies based on country of birth, as in our study, exclude
second-generation immigrants. A specific focus on this group will
enable subsequent investigation of changes in the patterns of
presentation and outcomes in these ethnic minority immigrant
groups due to factors such as acculturation and utilization of
screening. Future research on racial disparities in early breast
cancer is warranted to investigate whether differences in tumor
biology, psychosocial, economic or cultural factors may underpin
the epidemiological findings.
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